GlassScriptPhysician profile
Indira Prado
NPI 1679593503
$7,342.99
in general payments reported to CMS, 2019-2025
48 companies · $1,193 in 2025
The $1,193 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,792 · 2022: $1,405 · 2023: $1,444 · 2024: $1,509 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,146.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $820.63 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $619.98 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $521.03 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.69 | 2021-2025 | Jardiance, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $372.01 | 2021-2025 | |
| Lilly USA, LLC | $353.39 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $349.13 | 2021-2025 | Xifaxan, Relistor |
| Merck Sharp & Dohme LLC | $318.49 | 2021-2025 | Verquvo, Capvaxive |
| Insulet Corporation | $268.36 | 2023-2025 | Omnipod |
| Astellas Pharma US INC | $253.64 | 2021-2024 | Veozah, Myrbetriq |
| Dexcom, INC. | $241.47 | 2021-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $232.51 | 2022-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $192.93 | 2021-2022 | |
| Corcept Therapeutics | $187.59 | 2021-2024 | Korlym |
| Edwards Lifesciences Corporation | $175.02 | 2024 | Sapien 3 Ultra Resilia |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $162.92 | 2024-2025 | Voquezna |
| Abbvie INC. | $154.10 | 2021-2025 | |
| Amgen INC. | $153.23 | 2021-2025 | Otezla, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $142.82 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $142.68 | 2021-2025 | Gvoke Hypopen, Keveyis |
| Takeda Pharmaceuticals U.S.A., INC. | $133.32 | 2021-2023 | Gattex, Vonvendi |
| Biohaven Pharmaceutical Holding Company LTD. | $128.37 | 2022 | |
| Alkermes, INC. | $113.83 | 2024 | Aristada, Lybalvi |
| Glaxosmithkline, LLC. | $94.88 | 2021-2023 | Nucala |
| E.R. Squibb & Sons, L.L.C. | $76.17 | 2022-2024 | Eliquis |
| Abbott Laboratories | $72.31 | 2021-2023 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $69.09 | 2021 | |
| Boston Scientific Corporation | $67.80 | 2022-2023 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $57.00 | 2021-2022 | |
| Radius Health, INC. | $47.15 | 2022-2023 | Tymlos |
| Exact Sciences Corporation | $45.47 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Scilex Pharmaceuticals INC. | $34.45 | 2021-2022 | |
| Philips North America LLC | $34.14 | 2022 | |
| Lundbeck LLC | $29.42 | 2024 | Rexulti |
| Alexion Pharmaceuticals, INC. | $27.34 | 2022 | |
| Medtronic, INC. | $26.39 | 2021-2022 | |
| Genzyme Corporation | $25.67 | 2023 | |
| Inspire Medical Systems, INC. | $23.56 | 2023 | Inspire |
| Teva Pharmaceuticals USA, INC. | $21.33 | 2021 | |
| Ardelyx, INC. | $20.95 | 2025 | Ibsrela |
| Gilead Sciences, INC. | $20.51 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.11 | 2021 | |
| Inogen, INC. | $19.05 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Vifor Pharma, INC. | $17.65 | 2021 | |
| Ucb, INC. | $17.00 | 2021 | |
| Averitas Pharma INC. | $15.73 | 2024 | Qutenza |
| Scpharmaceuticals INC. | $15.63 | 2024 | |
| Beta Bionics, INC. | $11.05 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indira Prado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.